
buzzrx.com
Mar 31, 2025, 20:43
Akhil Santhosh: Pembrolizumab and lenvatinib show promise in mesothelioma treatment
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“Pembrolizumab + lenvatinib has encouraging responses in malignant mesothelioma patients as second line post-progression on nivo-ipi in the PEMMELA 2 trial.”
More posts featuring Akhil Santhosh.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 3, 2025, 18:37
Apr 3, 2025, 17:06
Apr 3, 2025, 16:56
Apr 3, 2025, 16:37